Close

Janssen (JNJ) Submits sNDA to U.S. FDA Based for XARELTO

April 28, 2017 4:33 PM EDT Send to a Friend
Janssen Research & Development, LLC (NYSE: JNJ) announced today it has submitted a supplemental New Drug Application (sNDA) to the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login